Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 19, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how the body's response to a specific respiratory virus, known as parainfluenza virus (PIV), might help predict the risk of developing a serious lung condition called bronchiolitis obliterans (BO) in patients who have received a stem cell transplant. BO is a type of lung damage that can occur after this type of transplant, and researchers want to understand whether certain blood and respiratory responses to PIV can indicate whether a patient might develop BO within two months of the infection.

To participate in this trial, adults who had a stem cell transplant less than two years ago may be eligible, provided they have a documented PIV infection and have shown symptoms for five days or less. Participants will undergo tests to assess their respiratory function and provide blood samples to help researchers analyze their immune response to the virus. Importantly, the trial is looking specifically at adults, and participants will need to provide informed consent before joining. This study aims to improve our understanding of the risks associated with respiratory infections in transplant recipients, which could ultimately help in managing their care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • Adults having received a hematopoietic stem cell transplantation for less than two years
• • Availability of respiratory function tests prior to infection
• • Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract
• • Symptoms of respiratory infection ≤ 5 days
• • Signed informed consent
• Exclusion Criteria:
• • Presence of a respiratory virus infection other than PIV
• • Viral respiratory co-infections
• • Bacterial or fungal respiratory infections
• • Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses
• • Patient not affiliated or beneficiary of a social security system
• • Patient deprived of liberty or protected
• • Pregnant or breastfeeding woman